MedTrace Logo

Network Osteoporosis Study

NCT00209469 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2005-09-21

No results posted yet for this study

Summary

This study is evaluating the use of the drug alendronate in preventing or reversing bone loss in children and adolescents receiving steroid medications.

Conditions

Interventions

DRUG

alendronate sodium

Sponsors & Collaborators

  • Elizabeth Glaser Pediatric AIDS Foundation

    collaborator OTHER

  • Glaser Pediatric Research Network

    lead NETWORK

Principal Investigators

  • Emily von Scheven, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Completion
2007-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00209469 on ClinicalTrials.gov